Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0774
    -0.0020 (-0.18%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2625
    +0.0003 (+0.03%)
     
  • USD/JPY

    151.3460
    -0.0260 (-0.02%)
     
  • Bitcoin USD

    69,866.39
    -487.73 (-0.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Moderna Proposes Filling Vials With Additional Doses Of COVID-19 Vaccine - Reuters

  • As Moderna Inc (NASDAQ: MRNA) approaches to manufacture almost one million doses a day, the company has proposed filling COVID-19 vaccine vials with additional doses of up to 15 versus 10 currently to ease the manufacturing crunch, Reuters reports.

  • Last week CNBC reported that Moderna had asked the FDA to fill its COVID-19 vaccine vials with up to five additional doses.

  • “Additional doses would help address capacity constraints, noting that “beyond the amount of drug product available, is how many vials you can fill in a given period of time,” said Moderna’s President, Stephen Hoge.

  • “Moderna would need to have further discussions with the FDA to assure the agency’s comfort with this approach before implementing,” the company said.

  • Yesterday, BofA Securities’ analyst downgraded the company’s stock from Neutral to Underperform and maintained a $150 price target, citing that MRNA shares have increased to difficult levels to justify a fundamental basis.

  • Price Action: MRNA shares are higher by 2.15% at $160.86 in the pre-market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement